An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
about
Phosphodiesterase 4-targeted treatments for autoimmune diseasesNew developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastSelective Phosphodiesterase Inhibitors for Psoriasis: Focus on ApremilastNew Oral Therapies for Psoriasis: A Comprehensive ReviewPhosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathologyEtiology and management of pyoderma gangrenosum: a comprehensive review.Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.Apremilast.Biochanin a, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness.Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.Small Molecules in the Treatment of Psoriasis.Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced AnesthesiaA meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyPhosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.Clinical potential of apremilast in the treatment of psoriatic arthritisThe effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.PDE4 inhibitors: a review of current developments (2005 - 2009).Targeting cancer with phosphodiesterase inhibitors.Emerging drugs for psoriatic arthritis.Apremilast as a treatment for psoriasis.Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.Current and emerging systemic treatment strategies for psoriasis.Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Apremilast for the treatment of psoriatic arthritis.Apremilast: first global approval.Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.Apremilast: A Review in Psoriasis and Psoriatic Arthritis.Apremilast for the treatment of psoriasis.Apremilast for the treatment of psoriatic arthritis.A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.PDE4B as a microglia target to reduce neuroinflammation.A Review of Psoriasis, Therapies, and Suicide.Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
P2860
Q21245284-76B05402-AFBA-4956-8BF8-AE9546BC6168Q22305855-C13EF6E6-7359-42C5-AF9F-5A4FB60FFFFBQ26781755-497C2651-BF93-47CC-9857-1DB80EB30BDDQ28071475-DB481A93-80FD-441F-8053-9AA829BB504BQ28389823-F546D725-FD79-4AE8-BB1F-D7ACCE354A53Q34030811-A8999E58-CE01-4F09-BBCB-4478805F70FEQ34091087-7EFFC34A-8053-4A48-8B43-AEAACCACD4A4Q34209887-681764C1-3CD4-414A-933B-14FE336590C4Q34548528-C1F01C44-ACDB-44C9-8433-812C35AF3D45Q34612877-A17AC5D6-FDE8-4DD7-8542-B914F72A98F1Q34706585-7BEF8A59-EB80-4BCF-A1A6-7BEE9299D7BFQ35576638-0CB26043-0A07-49AD-8DB5-6AD639B09DD0Q35740706-B67FD31C-4BEE-4F04-81CA-396B32BBCA14Q35792013-235C91CF-F726-49ED-ACF2-36D9CBC6280CQ35937121-3CF2CDF9-0F63-4749-8254-D930CE48FDCDQ36061710-84CD5869-D678-44C5-909B-7079284B78DCQ36866954-B9ADE0FA-C3B1-4444-8733-C6C3BA1EB077Q36923514-568B4058-F56C-4129-B9AA-5594DD2049D6Q37031662-C6CF7A61-4490-4F3F-8A74-58C6AAA0A7F4Q37104915-BA5EB5FB-38FC-4CD8-B109-2793871E71BDQ37462071-950F5712-690A-4C7B-86FC-550D6D78372AQ37615398-0A04F927-286F-4CD6-BC90-2DC03C61D331Q37650389-49429A8E-773E-4E14-8983-A6C835AF891CQ37763192-2EB62858-BE09-4190-B92D-EFFEF2451AC6Q38019980-1D4F1192-BC9B-40DA-B4CB-BAD3391E7A22Q38032568-E936DECE-3D82-4019-928C-283D54AF2A25Q38039491-8A70EE40-8941-4729-90F8-F1A397E19948Q38098466-F7C9A93A-62D7-4B2B-AFFB-DB05CCC18E2BQ38202205-74A0A8CB-031B-42C0-AF60-2F9520ED041AQ38209439-32F7C69A-4914-4FDA-99F2-1D44A4BF54F8Q38416536-6D7FA06A-FE26-4D9C-AC45-7D2C9B7CD841Q38556637-3A6B7DBC-6642-44DF-8FB0-6F0054341F9AQ38561061-29FF01DF-F725-4199-A850-8AE402A25788Q38616811-29D40A41-7E2A-43CA-BB95-0E22A7EAA712Q38675867-783D8C21-5B47-4F90-8443-AE4DDCA77638Q38753877-972F9028-2B96-492F-8916-2B3A5685D6B8Q38796315-79736B88-1962-420A-9827-1BB1C10AC783Q38840271-DB569FA2-F5EB-4D33-80FC-11C6F50E9865Q38885459-93C7BC1B-6EC2-414E-B491-77FDA9080897Q39141679-146E295C-06E2-4229-B9C8-5B1A7EB8FE09
P2860
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
An open-label, single-arm pilo ...... nflammatory agent, apremilast.
@en
An open-label, single-arm pilo ...... nflammatory agent, apremilast.
@nl
type
label
An open-label, single-arm pilo ...... nflammatory agent, apremilast.
@en
An open-label, single-arm pilo ...... nflammatory agent, apremilast.
@nl
prefLabel
An open-label, single-arm pilo ...... nflammatory agent, apremilast.
@en
An open-label, single-arm pilo ...... nflammatory agent, apremilast.
@nl
P2093
P356
P1476
An open-label, single-arm pilo ...... nflammatory agent, apremilast.
@en
P2093
A B Gottlieb
J B Zeldis
J G Krueger
P304
P356
10.1185/030079908X301866
P407
P577
2008-04-16T00:00:00Z